Editor's Pick
Stanford researchers said the cost of their approach is in line with Illumina sequencing but did not share data on error rate and other benchmarks at this time.
The purchase of GeneDx from Opko Health will help Sema4 accelerate its push into whole-exome sequencing and grow in rare disease diagnostics.
Protein-Based Liquid Biopsy Panel Assesses Tumor Microenvironment, Shows Prognostic Potential
Premium
A panel of 13 circulating proteins related to the tumor microenvironment may provide prognostic clues to prostate cancer progression.
Banner Year for Blood-Based Cancer Screening in 2021, but Reimbursement and Utility Hurdles Loom
Premium
New companies claimed stakes during the year, established firms solidified their plans and data, and Grail launched the first genomic multi-cancer early detection test.
Diagnostic Developers Pursue SARS-CoV-2 Omicron Assays for Surveillance, Potential Clinical Use
Premium
The FDA thus far has not been interested in PCR tests to identify specific SARS-CoV-2 variants, but that may be changing with the emergence of Omicron.